On May 21, the FDA posted new and revised versions of the following Import Alerts on the detention without physical examination of:
The U.S. District Court for the Eastern District of New York on May 16 issued a temporary restraining order against two logistics companies, barring them from using the U.S. Postal Service to ship packages with counterfeit postage.
Letex Apparels, a Hong Kong trading company, filed suit in the U.S. District Court for the Central District of California alleging that CBP negligently seized or forfeited 26,016 of the company's imported garments valued at $460,743.36. The company argued that, in handling its merchandise, CBP failed to "exercise due care" in handling the goods and violated the company's Fourth Amendment right against unreasonable seizure, the Administrative Procedure Act and a federal rule of criminal procedure requiring the return of property held by the government that isn't needed for evidentiary purposes (Letex Apparels Co. v. United States, C.D. Cal. # 2:25-04462).
CBP issued the following releases on commercial trade and related matters:
A listing of recent Commerce Department antidumping and countervailing duty messages posted on CBP's website May 21, along with the case number(s) and CBP message number, is provided below. The messages are available by searching for the listed CBP message number at CBP's ADCVD Search page.
The U.S. is the country of origin for platform software manufactured by Unifyia, according to a May 15 final determination announced via notice set for publication in the Federal Register.
Canada is the country of origin for two models of meeting tables manufactured by Global Industries, according to a notice released by CBP May 22.
CBP recently ruled which country would be the country of origin for Biomedix Selec-3 Multiple Drop Intravenous Product under five different scenarios, according to a notice released by the agency May 22
CBP has released its May 21 Customs Bulletin (Vol. 59, No. 21). While it contains no ruling notices, it includes four Court of International Trade slip opinions.
In the wake of President Donald Trump's May 12 executive order on prescription drug prices, CBP warned that it would "pursue any violations to the fullest extent possible" if it discovers that a party is failing to correctly input values related to prescription drug prices.